Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Short Interest Update

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) was the recipient of a large increase in short interest during the month of July. As of July 31st, there was short interest totaling 126,080 shares, an increase of 424.7% from the July 15th total of 24,029 shares. Based on an average daily volume of 6,655,441 shares, the short-interest ratio is currently 0.0 days. Approximately 5.3% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on LABT shares. Wall Street Zen cut Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Weiss Ratings started coverage on Lakewood-Amedex Biotherapeutics in a report on Monday, July 20th. They issued a “sell (e-)” rating for the company. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Lakewood-Amedex Biotherapeutics Trading Down 1.3%

Shares of NASDAQ LABT traded down $0.03 during midday trading on Thursday, reaching $2.33. 277,883 shares of the company traded hands, compared to its average volume of 1,325,166. The firm has a market capitalization of $5.52 million and a P/E ratio of -1.17. The stock’s 50-day moving average is $3.54. Lakewood-Amedex Biotherapeutics has a 52 week low of $1.66 and a 52 week high of $98.20.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last announced its earnings results on Friday, May 22nd. The company reported ($2.00) earnings per share (EPS) for the quarter. As a group, equities analysts anticipate that Lakewood-Amedex Biotherapeutics will post 2.52 earnings per share for the current fiscal year.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.